Kyle Fargen to Clinical Trials as Topic
This is a "connection" page, showing publications Kyle Fargen has written about Clinical Trials as Topic.
Connection Strength
0.427
-
Fiorella DJ, Fargen KM, Mocco J, Albuquerque F, Hirsch JA, Chen M, Gupta R, Linfante I, Mack W, Rai A, Tarr RW. Thrombectomy for acute ischemic stroke: an evidence-based treatment. J Neurointerv Surg. 2015 May; 7(5):314-5.
Score: 0.113
-
Goyal M, Almekhlafi M, Menon B, Hill M, Fargen K, Parsons M, Bang OY, Siddiqui A, Andersson T, Mendes V, Davalos A, Turk A, Mocco J, Campbell B, Nogueira R, Gupta R, Murphy S, Jovin T, Khatri P, Miao Z, Demchuk A, Broderick JP, Saver J. Challenges of acute endovascular stroke trials. Stroke. 2014 Oct; 45(10):3116-22.
Score: 0.109
-
Fargen KM, Meyers PM, Khatri P, Mocco J. Improvements in recanalization with modern stroke therapy: a review of prospective ischemic stroke trials during the last two decades. J Neurointerv Surg. 2013 Nov; 5(6):506-11.
Score: 0.096
-
Fargen KM, Mocco J, Hoh BL. Promising new aneurysm occlusion and clinical outcome results from CCT and HELPS. World Neurosurg. 2010 Oct-Nov; 74(4-5):389-90.
Score: 0.085
-
Goyal M, Fargen KM, Turk AS, Mocco J, Liebeskind DS, Frei D, Demchuk AM. 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. J Neurointerv Surg. 2014 Mar; 6(2):83-6.
Score: 0.024